Opioid neuropeptide genotypes in relation to heroin abuse: Dopamine tone contributes to reversed mesolimbic proenkephalin expression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 2, 2008, Pages 786-791

  Nikoshkov, Andrej ^a   Drakenberg, Katarina ^a   Wang, Xinyu ^a   Horvath, Monika Cs ^b   Keller, Eva ^b   Hurd, Yasmin L ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Catecholamine O methyltransferase; Drug abuse; Mu opioid receptor; Nucleus accumbens; Prodynorphin

Indexed keywords

CATECHOL METHYLTRANSFERASE; PRODYNORPHIN; PROENKEPHALIN;

ARTICLE; CONTROLLED STUDY; FETUS; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HEROIN DEPENDENCE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADULT; ANALGESICS, OPIOID; AUTOPSY; BRAIN; DOPAMINE; ENKEPHALINS; FEMALE; GENE EXPRESSION REGULATION; HEROIN; HUMANS; MALE; NEUROPEPTIDES; NUCLEUS ACCUMBENS; PROTEIN PRECURSORS; RECEPTORS, OPIOID, MU; SUBSTANCE-RELATED DISORDERS; TYROSINE 3-MONOOXYGENASE;

EID: 38649097175     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0710902105     Document Type: Article

References (40)

1. Hauser KF, et al. (2005) Pathobiology of dynorphins in trauma and disease. Front Biosci 10:216-235.
2. Kelley AE, et al. (2002) Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 76:365-377.
3. Drolet G, et al. (2001) Role of endogenous opioid system in the regulation of the stress response. Prog Neuropsychopharmacol Biol Psychiatry 25:729-741.
4. Goldman D, Oroszi G, Ducci F (2005) The genetics of addictions: Uncovering the genes. Nat Rev Genet 6:521-532.
5. Tsuang MT, et al. (1998) Co-occurrence of abuse of different drugs in men: The role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 55:967-972.
6. Drakenberg K, et al. (2006) Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci USA 103:7883-7888.
7. Bart G, et al. (2004) Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry 9:547-549.
8. Oslin DW, et al. (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546-1552.
9. Comings DE, et al. (1999) The proenkephalin gene (PENK) and opioid dependence. NeuroReport 10:1133-1135.
10. Zimprich A, et al. (2000)Anallelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J Neurochem 74:472-477.
11. Rockman MV, et al. (2005) Ancient and recent positive selection transformed opioid cis-regulation in humans. PLoS Biol 3:e387.
12. Dahl JP, et al. (2005) Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence. Am J Med Genet B Neuropsychiatr Genet 139:106-108.
13. Chen AC, et al. (2002) Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet 114:429-435.
14. Nakano K, Kayahara T, Tsutsumi T, Ushiro H (2000) Neural circuits and functional organization of the striatum. J Neurol 247(Suppl 5):V1-V15.
15. Matsumoto M,et al. (2003) Catechol O-methyltransferase mRNA expression in human and rat brain: Evidence for a role in cortical neuronal function. Neuroscience 116:127-137.
16. Egan MF, et al. (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917-6922.
17. Barnett JH, Jones PB, Robbins TW, Muller U (2007) Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function:Ameta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry 12:502-509.
18. Meyer-Lindenberg A, et al. (2005) Midbrain dopamine and prefrontal function in humans: Interaction and modulation by COMT genotype. Nat Neurosci 8:594-596.
19. Akil M, et al. (2003) Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 23:2008-2013.
20. Lachman HM, et al. (1996) Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243-250.
21. Bilder RM, Volavka J, Lachman HM, Grace AA (2004) The catechol-O-methyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29:1943-1961.
22. Wolf ME, Roth RH (1990) Autoreceptor regulation of dopamine synthesis. Ann NY Acad Sci 604:323-343.
23. O'Hara CM, Uhland-Smith A, O'Malley KL, Todd RD (1996) Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J Pharmacol Exp Ther 277:186-192.
24. Haber SN, Fudge JL (1997) The primate substantia nigra and VTA: Integrative circuitry and function. Crit Rev Neurobiol 11:323-342.
25. Wang GJ, Yang P, Xie HG (2006) Gene variants in noncoding regions and their possible consequences. Pharmacogenomics 7:203-209.
26. Ellgren M, Spano SM, Hurd YL (2007) Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32:607-615.
27. Sesack SR, Carr DB (2002) Selective prefrontal cortex inputs to dopamine cells: Implications for schizophrenia. Physiol Behav 77:513-517.
28. Surmeier DJ, et al. (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228-235.
29. Yavich L, et al. (2007) Site-specific role of catechol-O- methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci 27:10196-10209.
30. Kelley AE (2004) Ventral striatal control of appetitive motivation: Role in ingestive behavior and reward-related learning. Neurosci Biobehav Rev 27:765-776.
31. Nicola SM, Taha SA, Kim SW, Fields HL (2005) Nucleus accumbens dopamine release is necessary and sufficient to promote the behavioral response to reward-predictive cues. Neuroscience 135:1025-1033.
32. Zubieta JK, et al. (2003) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299:1240-1243.
33. Mattay VS, et al. (2003) Catechol O-methyltransferase Val158-Met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 100:6186-6191.
34. Ray R, et al. (2005) A functional prodynorphin promoter polymorphism and opioid dependence. Psychiatr Genet 15:295-298.
35. Diatchenko L, et al. (2005) Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 14:135-143.
36. Wang X, et al. (2004) In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol Psychiatry 56:909-915.
37. Weber JL, May PE (1990) Dinucleotide repeat polymorphism at the PENK locus. Nucleic Acids Res 18:2200.
38. Noda M, et al. (1982) Isolation and structural organization of the human preproenkephalin gene. Nature 297:431-434.
39. Nikoshkov A, et al. (2005) Prodynorphin transcripts and proteins differentially expressed and regulated in the adult human brain. FASEB J 19:1543-1545.
40. Parent A, Côté P-Y, Lavoie B (1995) Chemical anatomy of primate basal ganglia. Prog Neurobiol 46:131-197.